GLP-1 FDA records, October 2026
In October 2026, FDA issued 1 warning letter naming a GLP-1 drug tracked here (September: 3) and posted 2 letters it had issued earlier. openFDA lists 10 recall reports for compounded or unapproved GLP-1 products with an FDA report date in October, from 3 firms (September: 0). The index holds 3 dated FDA statements from October 2026. This report was frozen on Nov 4, 2026 and does not change when the records are refreshed.
Counts against September 2026
| Record | October 2026 | September 2026 |
|---|---|---|
| FDA warning letters issued | 1 | 3 |
| Letters posted this month, issued earlier | 2 | 5 |
| Recall reports with an FDA report date this month | 10 | 0 |
| Recall reports initiated this month | 0 | 10 |
| 503B facilities with a last inspection this month | 0 | 9 |
| Dated FDA statements | 3 | 0 |
| Federal Register documents | 0 | 0 |
Prior-month counts were taken from the records on the day this report was frozen, Nov 4, 2026. FDA posts some letters weeks after it issues them, so a later count for a past month can be higher.
FDA warning letters issued in October 2026
| Later letters FDA lists | Letter | ||||
|---|---|---|---|---|---|
| Oct 30, 2026 | RonanRx, Inc. dba RonanRx | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
A warning letter states FDA’s view when it was issued; it is not a court finding, and the company may have responded since. The later-letters column repeats what FDA’s warning letter index lists for each letter.
Letters FDA posted in October 2026 that were issued earlier
| Later letters FDA lists | Letter | ||||
|---|---|---|---|---|---|
| Sep 24, 2026 | Cheap Medicine Shop/www.cheapmedicineshop.com | Unapproved New Drugs/Misbranded (Internet Pharmacy) | Semaglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 23, 2026 | Online Generic Medicine/www.onlinegenericmedicine.com | Unapproved New Drug/Misbranded (Internet Pharmacy) | Semaglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
A warning letter states FDA’s view when it was issued; it is not a court finding, and the company may have responded since. The later-letters column repeats what FDA’s warning letter index lists for each letter.
Recall reports with an FDA report date in October 2026
| Record | ||||||
|---|---|---|---|---|---|---|
| Sep 25, 2026 | Houston Rx LLC | Tirzepatide/Niacinamide 2mL vial (40 MG per Vial) Inj 20mg/2mg/mL, RX Only, Houston RX LLC, 15430 Vantage Parkway E STE 220, Houston, TX 77032. | Lack of assurance of sterility. | Class II | Ongoing | D-0040-2027 |
| Sep 10, 2026 | Carolina Infusion, LLC | TIRZEPATIDE 26 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescription, Carolina Infus... | Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product. | Class II | Ongoing | D-0017-2027 |
| Sep 10, 2026 | Carolina Infusion, LLC | SEMAGLUTIDE 3 MG/ML INJECTABLE, 8 x 0.1 mL syringes, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936 | Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product. | Class II | Ongoing | D-0018-2027 |
| Sep 10, 2026 | Carolina Infusion, LLC | SEMAGLUTIDE/CYANOCOBALAMIN 3/2 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescriptio... | Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product. | Class II | Ongoing | D-0019-2027 |
| Sep 10, 2026 | Carolina Infusion, LLC | SEMAGLUTIDE/CYANOCOBALAMIN 9/2 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescription... | Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product. | Class II | Ongoing | D-0026-2027 |
| Sep 10, 2026 | Carolina Infusion, LLC | TIRZEPATIDE/CYANOCOBALAMIN 26/2 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescriptio... | Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product. | Class II | Ongoing | D-0027-2027 |
| Sep 10, 2026 | Carolina Infusion, LLC | TIRZEPATIDE/CYANOCOBALAMIN 64/2 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescriptio... | Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product. | Class II | Ongoing | D-0028-2027 |
| Sep 10, 2026 | Carolina Infusion, LLC | TIRZEPATIDE/CYANOCOBALAMIN 76/2 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescriptio... | Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product. | Class II | Ongoing | D-0029-2027 |
| Sep 10, 2026 | Carolina Infusion, LLC | TIRZEPATIDE/CYANOCOBALAMIN 85/2 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescriptio... | Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product. | Class II | Ongoing | D-0030-2027 |
| Sep 24, 2026 | Apothecary Pharma LLC | Tirzepatide Injection, 18mg/mL, 4 mL Sterile Multi-Dose Vial, Rx only, Apothecary Pharma, LLC, 1913 Evans Road, Cary, NC 27513, NDC 85091-001-18. | Lack of Assurance of Sterility | Class II | Ongoing | D-0036-2027 |
503B facility inspections
No facility on FDA’s 503B list showed a last inspection date in October 2026 when this report was frozen.
Dated FDA statements
- Oct 1, 2026: FDA states that retatrutide and cagrilintide cannot be used in compounding under federal law and are not components of FDA-approved drugs. FDA states it has warned telehealth companies for marketing unapproved drugs such as retatrutide, API distributors for selling retatrutide and other GLP-1 drugs to compounders, and outsourcing facilities for repackaging retatrutide. Source: FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
- Oct 1, 2026: FDA states it has warned companies that sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide falsely labeled “for research purposes” or “not for human consumption,” sold directly to consumers with dosing instructions. Source: FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
- Oct 1, 2026: FDA states that salt forms such as semaglutide sodium and semaglutide acetate are different active ingredients than those in the approved drugs, and that it is not aware of any lawful basis for their use in compounding. Source: FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
FDA’s page does not date each paragraph; the date shown is the page’s “content current as of” date.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA warning letters (fda.gov full-text search)
- openFDA drug recall enforcement reports
- FDA Registered Outsourcing Facilities (503B)
- FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
Records last pulled Nov 4, 2026. Every entry links to the original public record.